中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
页索引超出范围
Press Release
2023.12.10
Haihe Biopharma Announces Results from the Phase Ib Study of EZH1/2 Inhibitor HH2853 presented at the 2023 ASH Annual Meeting
2023.11.18
Haihe Biopharma Announces CDE Granted Breakthrough Therapy Designation to Gumarontinib for Non-small Cell Lung Cancer with MET Overexpression
2023.11.09
New Hope for Diabetic Foot Ulcers - " Fespixon®" Approved in China
2023.09.08
Haihe Biopharma Announces New Drug Application in Japan for MET inhibitor - Gumarontinib (SCC244) in Non-Small Cell Lung Cancer with MET exon 14 skipping mutation
2023.07.12
Haihe Announces First Patient Treated in China in SCC244-G303 Phase III Trial
2023.06.04
Haihe Biopharma Announces Preliminary Results from the Phase 1 Part of a First-in-Human Phase I/II Study of EZH1/2 Inhibitor HH2853 in the Epithelioid Sarcoma Population at ASCO Annual Meeting 2023
2023.04.17
Haihe Biopharma Announces Preliminary Results of the First-in-Human Clinical Study of EZH1/2 Inhibitor HH2853 at AACR Annual Meeting 2023
2023.04.07
Haihe Biopharma Announces the Clinical Results of Gumarontinib (INN) in The eClinicalMedicine
1
2
3
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
